Skip to main content

Bio-Techne Corp (TECH) Stock Analysis

Falling Knife setup

Buy WaitModerate Confidence

Healthcare · Biotechnology

Wait for pullback to $41.06. At $46.01 the A.R:R is 1.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $41.06 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Negative momentum; Below 200-day MA.

Bio-Techne develops and manufactures life science reagents, instruments, and diagnostic products in two segments: Protein Sciences (~72% of fiscal 2025 net sales) and Diagnostics & Spatial Biology (~28%). Products are sold to pharmaceutical, biotech, academic, and clinical... Read more

$46.01+19.7% A.UpsideScore 5.5/10#43 of 157 Biotechnology
QualityF-score8 / 9FCF yield4.21%
IncomeYield0.70%(5y avg 0.43%)Payout45.71%sustainable
Entry $41.06(Support Atr Sticky)Stop $35.04Target $53.43(analyst − 13%)A.R:R 1.2:1Setup A.R:R 3.1:1
Analyst target$61.42+33.5%12 analysts
$53.43our TP
$46.01price
$61.42mean
$75

Wait for pullback to $41.06. At $46.01 the A.R:R is 1.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $41.06 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Negative momentum; Below 200-day MA. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 5.5/10, moderate confidence.

Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.

Val5.7Qual6.7Grw6.0Mom3.0Sent7.6Ins5.2Peer3.6Tech6.0Risk4.15.5OVERALL

Recent Developments — Bio-Techne Corp

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Positive news sentiment (+0.67)
Risks
Negative momentum
Below 200-day MA

Key Metrics

P/E (TTM)65.0
P/E (Fwd)22.0
Mkt Cap$7.1B
EV/EBITDA19.7
Profit Mgn9.0%
ROE5.3%
Rev Growth-1.5%
Beta1.41
Dividend0.70%
Rating analysts23

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C1.83bearish
IV51%elevated
Max Pain$35-23.9% vs spot

Material Events(8-K, last 90d)

  • 2026-02-11Item 5.02MEDIUM
    Dr. Matt McManus (DSS Segment President) transitioning from role effective March 1, 2026. Steve Crouse appointed as DSS President effective March 1, 2026; currently SVP Analytical Solutions. Successor named.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.0
Ma Position
1.5
Rsi
3.5
Obv
10.0
Volume accumulation (rising OBV)Below 200-MA, MA slope flat

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
3.2
Value Rank
4.2
Quality Rank
7.0
GatesMomentum 3.0<4.5A.R:R 1.2 < 1.5@spotDeath cross (50MA < 200MA)Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 77d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Aggressive
RSI
32 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $43.12Resistance $57.46

Price Targets

$35
$41
$53
A.Upside+16.1%
A.R:R1.2:1
Setup A.R:R (at entry)3.1:1

Position Sizing

ConvictionMedium conviction
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! NEWS_MOD=+1: HOLD_IF_HOLDING → STRONG_BUY_WAIT
! Momentum score 3.0/10 — below 4.5 minimum
! Reward/Risk 1.2:1 at current price — below 1.5:1 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-05 (77d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TECH stock a buy right now?

Wait for pullback to $41.06. At $46.01 the A.R:R is 1.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $41.06 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Negative momentum; Below 200-day MA. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $53.43 (+16.1%), stop $35.04 (−31.3%), Setup A.R:R 3.1:1. Score 5.5/10, moderate confidence.

What is the TECH stock price target?

Take-profit target: $53.43 (+19.7% upside). Target $53.43 (+16.1%), stop $35.04 (−31.3%), Setup A.R:R 3.1:1. Stop-loss: $35.04.

What are the risks of investing in TECH?

Negative momentum; Below 200-day MA.

Is TECH overvalued or undervalued?

Bio-Techne Corp trades at a P/E of 65.0 (forward 22.0). TrendMatrix value score: 5.7/10. Verdict: Buy (Wait for Entry).

What do analysts say about TECH?

23 analysts cover TECH with a consensus score of 4.0/5. Average price target: $61.

What does Bio-Techne Corp do?Bio-Techne develops and manufactures life science reagents, instruments, and diagnostic products in two segments:...

Bio-Techne develops and manufactures life science reagents, instruments, and diagnostic products in two segments: Protein Sciences (~72% of fiscal 2025 net sales) and Diagnostics & Spatial Biology (~28%). Products are sold to pharmaceutical, biotech, academic, and clinical customers globally; no single customer exceeded 10% of either segment's net sales.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · ARGX (argenx SE) · ADMA (ADMA Biologics Inc) · HALO (Halozyme Therapeutics, Inc.)